How is primary urinary bladder adenocarcinoma staged using the AJCC/UICC TNM system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Staging of Urinary Bladder Adenocarcinoma

Primary urinary bladder adenocarcinoma is staged using the AJCC/UICC TNM (8th edition) staging system, identical to the system used for urothelial carcinoma of the bladder 1.

TNM Staging Framework

The staging system applies uniformly to all histologic subtypes of bladder cancer, including adenocarcinoma. The key components are:

T (Primary Tumor) Categories

  • Ta: Non-invasive papillary carcinoma confined to mucosa
  • T1: Invasion into lamina propria (submucosa)
  • T2: Invasion into detrusor muscle
    • T2a: Superficial muscle invasion (inner half)
    • T2b: Deep muscle invasion (outer half)
  • T3: Invasion into perivesical tissue
  • T4: Invasion into adjacent organs
    • T4a: Prostatic stroma, seminal vesicles, uterus, or vagina
    • T4b: Pelvic wall or abdominal wall 1

N (Regional Lymph Nodes) Categories

The 8th edition introduced critical changes to nodal staging:

  • N0: No regional lymph node metastasis
  • N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal/external iliac, or sacral) OR single common iliac lymph node
  • N2: Multiple regional lymph node metastases in the true pelvis OR multiple common iliac lymph nodes
  • N3: Lymph node metastasis to common iliac nodes 1, 2

Important note: Perivesical lymph node involvement is now classified as N1 (not N2 as in the 7th edition), representing a significant staging change 3, 2.

M (Distant Metastasis) Categories

  • M0: No distant metastasis
  • M1a: Distant metastasis limited to lymph nodes beyond common iliac nodes
  • M1b: Non-lymph node distant metastases 1, 2

Stage Groupings

The 8th edition subdivided stages III and IV:

  • Stage I: Ta-T1, N0, M0
  • Stage II: T2, N0, M0
  • Stage IIIA: T3-T4a, N0, M0 OR T1-T4a, N1, M0
  • Stage IIIB: T1-T4a, N2-N3, M0
  • Stage IVA: T4b, any N, M0 OR any T, any N, M1a
  • Stage IVB: any T, any N, M1b 1, 2

Critical change: N1-N3 disease was previously grouped within stage IV regardless of T stage; now N1 disease is stage IIIA and N2-N3 is stage IIIB when combined with T1-T4a tumors 1, 2.

Special Considerations for Adenocarcinoma

Urachal vs. Non-Urachal Adenocarcinoma

While both subtypes use the same TNM staging system, urachal adenocarcinoma can be distinguished pathologically by its location (dome/anterior wall), relationship to the urachus, and absence of cystitis cystica/cystitis glandularis in adjacent bladder 4, 5. When applying unified TNM staging, urachal adenocarcinoma may show better survival in advanced disease (pT3-T4), though both subtypes have comparable overall prognosis 4.

Diagnostic Confirmation Requirements

Adequate staging requires deep muscle (muscularis propria) in the resection specimen 1. Small fragments with few muscle fibers are inadequate for accurate T-stage determination. For adenocarcinoma specifically, immunohistochemistry is essential to distinguish primary bladder adenocarcinoma from secondary involvement:

  • Primary bladder: CK7-, CK20+, CDX2+, membranous β-catenin+, SATB2-, GATA3- 6, 7
  • This pattern helps exclude colorectal metastasis, which is the most common differential diagnosis 5, 6, 7

Clinical vs. Pathologic Staging

  • "c" prefix: Clinical staging based on bimanual examination under anesthesia, endoscopic surgery (TURBT/biopsy), and imaging
  • "p" prefix: Pathologic staging based on cystectomy and lymph node dissection 1

Pathologic staging is definitive and supersedes clinical staging when available.

Prognostic Implications

Depth of invasion (T stage) is the most important determinant of prognosis and treatment 1. Primary bladder adenocarcinoma typically presents at advanced stages, contributing to its poor prognosis compared to urothelial carcinoma 5. The T2 substaging (T2a vs. T2b) has validated prognostic significance, with deep muscle invasion (T2b) associated with significantly worse recurrence-free survival (58.7% vs. 73.2%) and cancer-specific survival (65.1% vs. 78.0%) 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.